Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies

NCT02189174 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02189174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02189174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
August 7, 2014
Completion date
November 12, 2015
Enrollment
31 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor